After two weeks of uncertainty, the path forward for cannabis on statutory health insurance prescriptions is now clear. The KBV (German Medical Association) and GKV-Spitzenverband (German Statutory Health Insurance Association) have agreed on a joint interpretation of the new rules. For patients undergoing ongoing extract therapy, this brings relief—but flowers remain excluded.
📑 Inhaltsverzeichnis
- What’s Been in Effect Since July 30
- The Clarification: Trial Requirement Only Where Approved Products Exist
- Existing Extract Patients Keep Their Coverage
- Flowers Remain Excluded; Patients Must Switch
- What This Means for Pharmacies and Practices
- What Affected Patients Should Know Now
- 💬 Fragen? Frag den Hanf-Buddy!
Since the GKV Contribution Rate Stabilization Act came into force, doctors‘ offices and pharmacies have grappled with uncertainty about what happens to existing cannabis therapies. One question loomed large: Must patients who have been stable on standardized extracts for years now undergo a six-month trial with an approved pharmaceutical product? On August 6, the KBV and GKV-Spitzenverband published a joint clarification. The answer is no.
What’s Been in Effect Since July 30
First, the facts—which have been reported inconsistently. The law was announced in the Federal Law Gazette on July 29, 2026 (BGBl. I No. 228) and came into force on July 30, 2026. Since then, dried cannabis flowers can no longer be prescribed at the expense of statutory health insurance. For remaining cannabis medications—standardized extracts, compounded preparations, and products containing dronabinol or nabilone—coverage continues. According to the KBV, the underlying conditions for insurance coverage of cannabis treatment have not changed.
The Clarification: Trial Requirement Only Where Approved Products Exist
The heart of the agreement concerns the new priority rule. The six-month trial with an approved cannabis pharmaceutical applies only to the indications for which that specific pharmaceutical product is approved. This has several practical implications:
- If there is no approved pharmaceutical product for an indication—such as severe pain—an extract or other cannabis medication can be prescribed immediately on first dispensing. A trial period is not required.
- The trial can be terminated early if the patient cannot tolerate the pharmaceutical or the therapy proves ineffective. Continued dispensing would then be uneconomical under cost-effectiveness rules.
- A second approved pharmaceutical for the same indication does not need to be tested additionally.
Existing Extract Patients Keep Their Coverage
For the largest group of concerned patients, the clarification brings definitive reassurance: Those who have been treated with extracts or compounded preparations continue to have coverage. Doctors can issue follow-up prescriptions, and in these cases, the requirement for a six-month trial with an approved pharmaceutical is waived.
This confirms what the Federal Health Ministry told us in advance:
„Already-started therapies with preparations (such as extracts) do not need to be switched.“
Federal Health Ministry on inquiry by Hanf Magazin
At that time, however, this was merely the Ministry’s legal opinion and was not binding on health insurance companies or medical review boards. Only the joint interpretation by the KBV and GKV-Spitzenverband creates the binding clarity needed in routine care.
Flowers Remain Excluded; Patients Must Switch
Cannabis flowers are not covered by this clarification. Since July 30, they can no longer be prescribed at health insurance expense—explicitly including therapies already underway. The Health Ministry stated:
„The exclusion from benefits applies from the effective date of the law, including for therapies already begun.“
Federal Health Ministry on inquiry by Hanf Magazin
Anyone previously receiving flowers on insurance must switch to another cannabis medication. According to the KBV, this generally requires a new health insurance approval. Exceptions apply to prescriptions from doctors exempt from prior approval requirements, including specialists in general medicine, neurology, and gynecology. They may voluntarily request approval if they wish to be covered. In all cases, the KBV advises careful documentation of the reason for the switch.
What This Means for Pharmacies and Practices
The agreement also clarifies where financial risk falls in routine care. The situation differs for oral extracts versus flowers.
In the days after the law took effect, pharmacies faced potential charge-backs on oral extracts because the law contained no transition clause. This concern is now outdated, as Dr. Christiane Neubaur, executive director of the Association of Cannabis-Supplying Pharmacies, clarified to Hanf Magazin: The risk now lies with the prescribing physician, in the form of potential recourse. Therefore, it is advisable to file a cost-coverage request with the health insurance company. Existing extract therapies can continue without filing a new request. The KBV also explicitly alerts practices to this recourse risk.
Flowers are a different matter. They are definitively excluded from coverage, and flower prescriptions cannot be filled since July 30. According to Neubaur, this applies explicitly even if the prescription was issued before July 30 but filled afterward. Pharmacies continue to face a charge-back risk in these cases.
The previously feared forced switching of stably-treated patients is also off the table. Neubaur explains:
„This compulsion to use cannabinoid-based pharmaceutical products no longer exists. Only within approved indication areas must pharmaceuticals be prescribed.“
Dr. Christiane Neubaur, Executive Director, Association of Cannabis-Supplying Pharmacies
What Affected Patients Should Know Now
If you are established on extracts, compounded preparations, or dronabinol, you do not need to switch therapy and require no new trial period. If you have been receiving flowers on insurance, you will be switched; flowers remain prescribable but only on private prescription, at your own cost. One affected patient described to us in an interview what this means for those dependent on precise control of their therapy. Which therapy is appropriate in each case is decided exclusively by the treating physician.
Regardless of this clarification, legal challenges to the flower exclusion continue. Individual patients have filed emergency motions at social courts, and the Association Cannabis as Medicine reports preparing a constitutional complaint with a specialist attorney. We have separately analyzed the specific legal arguments at play.
Note: This article reflects the coverage rules as of August 7, 2026, and does not constitute legal or medical advice. Questions about your personal therapy belong with your doctor.
Nutzt du aktuell Cannabis auf Rezept von der Krankenkasse?
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
